Creating novel hematopoietic cell lines by expressing altered re

Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Method of regulating cell metabolism or physiology

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

435 691, 435325, C12N 516

Patent

active

058307605

DESCRIPTION:

BRIEF SUMMARY
FIELD OF THE INVENTION

This invention relates to genetic engineering and particularly to hematopoietic cell lines bearing altered retinoic acid receptors.


BACKGROUND OF THE INVENTION

Abbreviations used herein include: APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; BFU-E, burst-forming unit-erythroid; CAT, chloramphenicol acetyltransferase; CFU-E, colony-forming unit-erythroid; CFU-GM, colony-forming unit-granulocyte/macrophage; Epo, erythropoietin; GM-CSF, granulocyte-macrophage colony stimulating factor; IL-3, interleukin-3; IL-6, interleukin-6; IL-7, interleukin-7; IL-11, interleukin-11; HS, horse serum; IgE R, immunoglobulin E receptor; RA, retinoic acid; RAR.alpha., retinoic acid receptor-.alpha.; RARs, retinoic acid receptors; RXR, retinoid X receptor; SCF, stem cell factor.
Retinoic acid (RA), the natural acidic derivative of vitamin A (retinol), is a critical molecule regulating growth and differentiation of a wide variety of cells. RA is thought to be centrally involved in epithelial differentiation (37; see the appended citations), plays a critical role as a tissue-specific morphogen during embryogenesis (50) and as a suppressor of malignant transformation of epithelial cells both in vitro (39) and in vivo (29). These diverse and complex biologic effects of RA are mediated through a number of closely related nuclear RA receptors (RARs) that are members of the steroid/thyroid hormone receptor superfamily and possess discrete DNA-binding and RA (ligand) binding domains (22).
The expression of RARs is widespread with RAR mRNA noted in most fetal and adult tissue (57). Unlike the steroid hormone receptors, the RA receptors as well as thyroid hormone receptors appear to be associated with chromatin and may be constitutively bound to cis-acting regulatory sequences in the absence of ligand (10, 35). Thus these receptors may have different regulatory roles in the absence and presence of ligand.
Several lines of indirect evidence suggest that RA and RA receptors may be involved in regulating the development of hematopoietic progenitors. For example, RA receptor mRNA (predominantly RAR.alpha.) is widely expressed in different hematopoietic cell types (18, 23, 34). Treatment of a human myeloid leukemia cell line HL-60 with all-trans retinoic acid (ATRA) induces these cells to undergo terminal neutrophilic differentiation, and this induction is directly mediated through RAR.alpha. (3, 8). In addition, human acute promyelocytic leukemia (APL) exhibits a specific 15:17 chromosome translocation involving RAR.alpha. which presumably results in the disruption of a normal, albeit unknown, regulatory function of this particular RA receptor (1, 2, 20, 21, 32). Furthermore, ATRA induces the leukemia cells from APL patients to differentiate into mature neutrophils both in vitro and in vivo (4, 5, 30, 55). However, it is currently unknown if RA and RA receptors might also be involved in regulating normal hematopoietic differentiation.
Normal hematopoietic differentiation involves a single primitive stem cell that gives rise to all the other types of hematopoietic cells. The existence of a common pluripotential stem cell that is the progenitor of all lymphoid, myeloid, and erythroid cells was initially demonstrated by transplantation experiments using bone marrow cells carrying X-ray-induced chromosomal markers (55a). More recently, direct marking of bone marrow cells with retroviral vectors has further confirmed the existence of a common lympho-hematopoietic progenitor cell (36a). Through a combination of physical and immunological purification methods, the murine lympho-hematopoietic progenitor cells have been purified to near homogeneity (47a). Their frequency is estimated to be only 0.01-0.005% of all nucleated cells in the bone marrow. The scarcity of the lympho-hematopoietic stem cells and the difficulty in their purification and maintenance have hampered efforts to purify appreciable numbers of these cells. If such cells were available as continuous cell lines, they could be used to dissect

REFERENCES:
Breitman, T.R., S.E. Selonick, and S.J. Collins. 1980. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc. Natl. Acad. Sci. USA 77: 2936-2940.
Collins, S.J., R.C. Gallo, and R.E. Gallagher. 1977. Continuous growth and differentiation of human myeloid leukemia cells in suspension culture. Nature 270; 347-349.
Collins, S.J., K. Robertson, and L. Mueller. 1990. Retinoic acid-induced granulocyte differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-.alpha.). Mol. Cell. Biol. 10:2154-2161.
Denburg, J.A. 1992. Basophil and mast cell lineages in vitro and in vivo. Blood 79: 846-860. (A review).
deThe, H., A. Marchio, P. Tiollais, and A. Dejean. 1989. Differential expression and ligand regulation of the retinoic acid receptor .alpha. and .alpha.' genes. EMBO J. 8: 429-433.
deThe, H., M. Vivanco-Ruiz, P. Tiollais, H. Stunnenberg, and A. Dejean. 1990. Identification of a retinoic acid responsive element in the retinoic acid receptor .alpha. gene. Nature 343: 177-180.
deThe, H., C. Chomienne, M. Lanotte, L. Degos, and A. Dejean. 1990. The t(15:17) translocation of acute promelocytic leukemia fuses the retinoic acid receptor .alpha. gene to a novel transcribed locus. Nature 347: 558-561.
Evans, R. 1988. The steroid and thyroid hormone receptor superfamily. Science 240: 889-895.
Gallagher, R., F. Said, I. Pua, P. Papenhausen, E. Paietta, and P. Wiernik. 1989. Expression of retinoic acid receptor .alpha. in human luekemia cells with variable responsiveness to retinoic acid. Leukemia 3: 789-795.
Gigure, V., E. Ong, P. Segui, and R. Evans. 1987. Identification of a receptor for the morphogen retinoic acid. Nature 330: 624-629.
Heyworth , C.M., T.M. Dexter, O. Kan ,and A.D. Whetton. 1990. Growth Factors 2: 197-211.
Largman, C., K. Detmer, J. Corral, F. Hack, and H. Lawrence. 1989. Expression of retinoic acid receptor alpha mRNA in human leukemic cells. Blood 74: 99-102.
Lotan, R. 1980. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochem. Biophys. Acta 605 : 33-91.
Spooncer, E.C., Boettingen, D. and T.M. Dexter. 1984. Nature 310: 228-230.
Spooncer, E., C. Heyworth, A. Dunn, and T.M. Dexter. 1986. Self-renewal and differentiation of interleukin-3-dependent multipotent stem cells are modulated by stromal cells and serum factors. Differentiation 31: 111-118.
Tsai, S., S. Bartelmez, R. Heyman, K. Damm, R. Evans and S.J. Collins. 1992. Genes & Development 6: 2258-2269.
Tsai, S.-F., D. Martin, L. Zon, A. D'Andrea, G. Wong, and S. Orkin. 1989. Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells. Nature 339: 446-451.
Umesono, K., V. Giguere, C. Glass, M. Rosenfeld, and R. Evans. 1988. Retinoic acid and thyroid hormone induce gene expression through a common responsive element. Nature 336: 262-265.
Zon, I.L., M.F. Gurish, R. Stevens, C. Mather, D.S. Reynolds, K.F. Austen, and S.H. Orkin. 1991. GATA-binding transcription factors in mast cells regulate the promoter of the mast cell carboxypeptidase A gene. J. Biol. Chem. 266: 22948-22953.
Tsai, S., and S.J. Collins. Aug. 1993. A dominant negative retinoic acid recept blocks neutrophil differentiation at the promyelocyte stage. Proc. Natl. Acad. Sci. USA 90: 7153-7157.
Tsai, S., et al. , "Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can racapitulate lymphoid, myeloid, and erythroid development," Genes and Development, 8:2831-2841, 1994.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Creating novel hematopoietic cell lines by expressing altered re does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Creating novel hematopoietic cell lines by expressing altered re, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Creating novel hematopoietic cell lines by expressing altered re will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-688549

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.